NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026

Area of Science:

• Oncology
• Urology
• Clinical Guidelines

Background:

• The NCCN Guidelines for Prostate Cancer provide comprehensive recommendations for diagnosis, staging, risk assessment, and treatment of prostate cancer.
• These guidelines cover localized, regional, recurrent, and metastatic disease stages.
• Regular updates ensure the guidelines reflect the latest scientific evidence and clinical consensus.

Purpose of the Study:

• To summarize key updates from the 2026 NCCN Guidelines for Prostate Cancer.
• To highlight changes specifically related to nonmetastatic prostate cancer management.
• To inform clinicians about revisions in risk stratification, active surveillance, and focal therapy recommendations.

Main Methods:

• Review of NCCN Guidelines Insights detailing panel discussions on 2026 updates.
• Focus on changes pertaining to nonmetastatic prostate cancer.
• Analysis of specific revisions concerning risk groups, active surveillance, and focal therapy.

Main Results:

• The very-low-risk group for prostate cancer has been eliminated from the guidelines.
• Updates have been made to the Principles of Active Surveillance.
• The guidelines now emphasize caution regarding the use of focal therapy in newly diagnosed patients.

Conclusions:

• The 2026 NCCN Guidelines for Prostate Cancer reflect significant adjustments in managing nonmetastatic disease.
• These updates aim to optimize patient care by refining risk assessment and treatment strategies.
• Clinicians should be aware of these changes for accurate prostate cancer management.